Nathan Vastesaeger

2.2k total citations
47 papers, 1.6k citations indexed

About

Nathan Vastesaeger is a scholar working on Rheumatology, Immunology and Genetics. According to data from OpenAlex, Nathan Vastesaeger has authored 47 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Rheumatology, 18 papers in Immunology and 11 papers in Genetics. Recurrent topics in Nathan Vastesaeger's work include Rheumatoid Arthritis Research and Therapies (39 papers), Spondyloarthritis Studies and Treatments (23 papers) and Psoriasis: Treatment and Pathogenesis (15 papers). Nathan Vastesaeger is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (39 papers), Spondyloarthritis Studies and Treatments (23 papers) and Psoriasis: Treatment and Pathogenesis (15 papers). Nathan Vastesaeger collaborates with scholars based in Belgium, United States and Germany. Nathan Vastesaeger's co-authors include Bert Vander Cruyssen, Eduardo Collantes‐Estévez, Daniel Aletaha, E. William St. Clair, Stephen Xu, Josef S Smolen, Joachim Sieper, Filip Van den Bosch, Herman Mielants and L Dewulf and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of the Rheumatic Diseases.

In The Last Decade

Nathan Vastesaeger

42 papers receiving 1.5k citations

Peers

Nathan Vastesaeger

RHEUM

IMMUN

HEMAT

OSM

SURGE

P. Nicaise‐Roland France

Marijn Vis Netherlands

Julio Ramírez Spain

John Han United States

Herbert Kellner Germany

José Fernando Molina Colombia

Sofia Ajeganova Sweden

P. L. C. M. van Riel Netherlands

Alberto Spindler Argentina

M V van Krugten Netherlands

P. Nicaise‐Roland France

Nathan Vastesaeger

931 ×0.7

RHEUM

396 ×0.6

IMMUN

262 ×0.6

HEMAT

43 ×0.3

OSM

152 ×1.3

SURGE

Citations per year, relative to Nathan Vastesaeger Nathan Vastesaeger (= 1×) peers P. Nicaise‐Roland

Countries citing papers authored by Nathan Vastesaeger

Since Specialization

Citations

This map shows the geographic impact of Nathan Vastesaeger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Vastesaeger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Vastesaeger more than expected).

Fields of papers citing papers by Nathan Vastesaeger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Vastesaeger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Vastesaeger. The network helps show where Nathan Vastesaeger may publish in the future.

Co-authorship network of co-authors of Nathan Vastesaeger

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Vastesaeger. A scholar is included among the top collaborators of Nathan Vastesaeger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Vastesaeger. Nathan Vastesaeger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Durez, Patrick, Karel Pavelká, María Alicia Lázaro, et al.. (2018). Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial. Clinical Rheumatology. 37(5). 1417–1420.

Vastesaeger, Nathan, Howard Amital, Karel Pavelká, et al.. (2016). Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab. Lara D. Veeken. 55(8). 1466–1476. 18 indexed citations

Sieper, Joachim, Martín Rudwaleit, Jan Lenaerts, et al.. (2016). Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Lara D. Veeken. 55(11). 1946–1953. 14 indexed citations

Vastesaeger, Nathan, Bert Vander Cruyssen, Juan Mulero, et al.. (2014). ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatología Clínica. 10(4). 204–209. 23 indexed citations

Combe, Bernard, Bhaskar Dasgupta, Ingrid Louw, et al.. (2013). Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Annals of the Rheumatic Diseases. 73(8). 1477–1486. 27 indexed citations

Sieper, Joachim, Jan Lenaerts, J. Wollenhaupt, et al.. (2013). Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Annals of the Rheumatic Diseases. 73(1). 101–107. 147 indexed citations

Cruyssen, Bert Vander, Nathan Vastesaeger, & Eduardo Collantes‐Estévez. (2013). Hip disease in ankylosing spondylitis. Current Opinion in Rheumatology. 25(4). 448–454. 63 indexed citations

Sieper, Joachim, Jan Lenaerts, J. Wollenhaupt, et al.. (2013). Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Annals of the Rheumatic Diseases. 73(1). 108–113. 42 indexed citations

Sieper, Joachim, Shankar Srinivasan, Omid Zamani, et al.. (2012). Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Annals of the Rheumatic Diseases. 72(10). 1621–1627. 94 indexed citations

10.

Vastesaeger, Nathan, Désirée van der Heijde, Robert D. Inman, et al.. (2011). Predicting the outcome of ankylosing spondylitis therapy. Annals of the Rheumatic Diseases. 70(6). 973–981. 141 indexed citations

11.

Baranauskaitė, Asta, Helena Raffayová, Nikolay V. Kungurov, et al.. (2011). Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Annals of the Rheumatic Diseases. 71(4). 541–548. 157 indexed citations

12.

Cruyssen, Bert Vander, Elisa Muñoz-Gomáriz, Pilar Font, et al.. (2009). Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Lara D. Veeken. 49(1). 73–81. 139 indexed citations

13.

Boonen, Annelies, Bert Vander Cruyssen, Kurt De Vlam, et al.. (2009). Spinal Radiographic Changes in Ankylosing Spondylitis: Association with Clinical Characteristics and Functional Outcome. The Journal of Rheumatology. 36(6). 1249–1255. 45 indexed citations

14.

Vastesaeger, Nathan, Stephen Xu, Daniel Aletaha, E. William St. Clair, & Josef S Smolen. (2009). A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Lara D. Veeken. 48(9). 1114–1121. 178 indexed citations

15.

Durez, Patrick, René Westhovens, Filip Van den Bosch, et al.. (2006). Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition.. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

16.

Vlam, Kurt De, Nathan Vastesaeger, Annelies Boonen, et al.. (2006). Belgian patients with familial and sporadic ankylosing spondylitis differ in disease phenotype. Ghent University Academic Bibliography (Ghent University). 54(9). 717. 2 indexed citations

17.

Hoecke, Helen Van, et al.. (2006). Classification and management of allergic rhinitis patients in general practice during pollen season. Allergy. 61(6). 705–711. 62 indexed citations

18.

Decroix, J., et al.. (2006). Desloratadine 5 mg once daily improves the quality of life of patients with chronic idiopathic urticaria. Journal of the European Academy of Dermatology and Venereology. 20(3). 288–292. 24 indexed citations

19.

Cruyssen, Bert Vander, Stijn Van Looy, Bart Wyns, et al.. (2006). Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Research & Therapy. 8(4). R112–R112. 46 indexed citations

20.

Westhovens, René, Patrick Durez, Jean‐Pierre Devogelaer, et al.. (2004). A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks is effective: A Belgian prospective study. Annals of the Rheumatic Diseases. 63. 90–90. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact